icon-folder.gif   Conference Reports for NATAP  
  16th European AIDS Conference
October 25-27 2017
Milan, Italy
Back grey_arrow_rt.gif
Bone and renal safety Week 48 subgroup analysis of EMERALD:A Phase III, randomised study evaluating switching from boosted protease inhibitors plus FTC/TDF to darunavir/cobicistat/emtricitabine/tenofovir alafenamide(D/C/F/TAF) in virologicallysuppressed, HIV-1-infected adults
  Reported by Jules Levin
16th European AIDS Conference, October 25-27, 2017. Milan
JR Arribas,1C Orkin,2J-M Molina,3J Eron,4E Van Landuyt,5E Lathouwers,5V Hufkens,5R Petrovic,5M Opsomer,5on behalf of the EMERALD study group 1Hospital UniversitarioLa Paz, IdiPAZ, Madrid, Spain; 2Barts Health NHS Trust, London, UK; 3Department of Infectious Diseases, St-Louis Hospital, University of Paris Diderot, Paris, France; 4The University of North Carolina School of Medicine, Chapel Hill, NC, USA; 5Janssen PharmaceuticaNV, Beerse, Belgium